Catherine C. Smith

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text

Vaccination, Vaccine Safety, Phase 1/2 +7

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2021 · 1.2K citations · Full text

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

Catherine C. Smith, Qi Wang, Chen-Shan Chin et al. · Nature · 2012 · 734 citations

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +10

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes et al. · The Lancet Oncology · 2017 · 484 citations · Full text

Selective Inhibition, Hematological Malignancy, Oncology +6

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

Christine M. McMahon, Timothy T. Ferng, Jonathan Canaani et al. · Cancer Discovery · 2019 · 412 citations · Full text